On April 15, 2024, the US Food & Drug Administration (FDA) announced the establishment of the Center for Drug Evaluation and Research (CDER) Center for Clinical Trial Innovation (C3TI). C3TI will serve as the central support hub for innovative approaches to clinical trials designed to improve the quality and efficiency of drug development and regulatory decision-making. Following a public solicitation of comments on the barriers of clinical trial designs, FDA determined that the establishment of C3TI would enhance CDER’s ability to address those barriers and foster innovation.
FDA Establishes CDER Center for Drug Innovation (C3TI)
By James Ravitz, Paul Gadiock, Jiayan Chen, Marissa Hill Daley, Nathan Gray and Karis Jackson on May 29, 2024
Posted In Employee Benefits, Health and Welfare Plans
![](https://www.employeebenefitsblog.com/wp-content/uploads/2024/08/Ravitz_J_ID_WB-150x150.jpg)
James (Jamie) Ravitz is the co-head of the Firm’s Life Sciences industry practice and head of McDermott’s Food and Drug Administration (FDA) practice. He works alongside clients across the entire spectrum of life sciences and healthcare law, including regulatory counsel, compliance, and investigations and government enforcement. He is particularly focused on Food and Drug Administration (FDA) regulatory counseling. Jamie works in partnership with companies and investors across the complete ecosystem of FDA-regulated products—drugs, devices, health technologies, biologics, food, cosmetics and cannabis— to help them achieve their business goals. Read James R. Ravitz's full bio.
![](https://www.employeebenefitsblog.com/wp-content/uploads/2024/05/Gadiock_P_27078_WB-150x150.jpg)
Paul Gadiock leverages his firsthand experience at the Food and Drug Administration (FDA) to provide life sciences, healthcare and other FDA-regulated companies with practical, strategic counsel at every phase of the product life cycle. Paul supports medical device, digital therapeutic, and biopharma companies, software as a medical device (SaMD) and clinical decision support (CDS) developers, and their investors on their FDA regulatory and due diligence needs, delivering premarket and postmarket regulatory guidance to maximize business outcomes. Read Paul S. Gadiock's full bio.
![](https://www.employeebenefitsblog.com/wp-content/uploads/2020/05/Chen.jpg)
Jiayan Chen is deeply experienced in the regulatory, transactional and strategic issues that arise when leveraging health information, biospecimens and technology to drive healthcare innovation and quality. She guides stakeholders on privacy compliance and research compliance and in the context of strategic initiatives and collaborations as they seek to harness the power of data, machine learning, DNA sequencing and technologies to develop and deploy new products and solutions and address challenges in healthcare delivery and payment. Read Jiayan Chen's full bio.
![](https://www.employeebenefitsblog.com/wp-content/uploads/2024/08/Hill-Daley_M_27103_WB-150x150.jpg)
Marissa Hill Daley focuses her practice on healthcare and US Food & Drug Administration (FDA) matters, including advising clients on regulatory compliance, government and internal investigations, and FDA marketing requirements. Marissa also defends clients against whistleblower qui tam suits that involve the False Claims Act and the Anti-Kickback Statute. Read Marissa Hill Daley's full bio.
![](https://www.employeebenefitsblog.com/wp-content/uploads/2024/05/Gray_N_26122_WB-150x150.jpg)
Nathan Gray is a member of the Healthcare Practice Group. While earning his law degree, Nathan served as a summer associate at McDermott. He was a legal fellow at Compassion and Choices in Portland, Oregon, and served as internal vice president of the Health Law Society at Duke University School of Law. Read Nathan Gray's full bio.
![](https://www.employeebenefitsblog.com/wp-content/uploads/2024/05/Jackson_K_19853_WB-150x150.jpg)
Karis Jackson advises healthcare clients on diverse transactional and regulatory issues related to managed care, healthcare policy, US Centers for Medicare & Medicaid Services due process, and Food & Drug Administration and Federal Trade Commission guidance. Her clients include private equity and practice management companies, public and private companies, and healthcare organizations. Read Karis Jackson's full bio.
Related Posts
- FDA Pushes to Diversify Clinical Studies, Releases Draft Industry Guidance
- Imported Drugs: (Possibly) Coming Soon to a State Near You
- Medicare Coverage of Wegovy Raises Questions Regarding the Affordability and Accessibility of Novel Medications
- 2024 Chart of Healthcare Regulations
- Medicare Drug Price Negotiation Program and Drug Pricing Reform: Eligible Drugs to Know and Understanding What’s Next
BLOG EDITORS
STAY CONNECTED
TOPICS
ARCHIVES
RECENT POSTS
- New IRS Revenue Procedure Affects Defined Benefit Pension Plan Sponsors
- Federal Court Invalidates Key Part of HHS OCR Bulletin Regarding Application of HIPAA to Online Tracking Technologies
- Pending California Law Undermines Growth of Digital Health Companies and Patient Access to Virtual Care
- FDA Pushes to Diversify Clinical Studies, Releases Draft Industry Guidance
- Assessing the Recent Claims Against Sellers and Other Non-Trustees in Lawsuits Relating to ESOPs
![McDermott Will & Emery LLP - Employee Benefits (ERISA) Law](https://www.employeebenefitsblog.com/wp-content/uploads/2020/11/McDermott-Will-Emery-LLP-Employee-Benefits-ERISA-Law.png)
![2023 Chambers USA - Ranked In. Top ranked chambers 2022](https://www.employeebenefitsblog.com/wp-content/uploads/2023/12/2023-Chambers-USA-Ranked-In.jpg)
![2023 Legal 500 US - Leading Firm US leading firm 2022](https://www.employeebenefitsblog.com/wp-content/uploads/2023/12/2023-Legal-500-US-Leading-Firm.jpg)
![2024 Best Law Firms - Standard Badge](https://www.employeebenefitsblog.com/wp-content/uploads/2023/12/2024-Best-Law-Firms-Standard-Badge.png)